News


Domain Therapeutics appoints Sylvie Ryckebusch to board of directors

Wednesday , 12 June 2019

Seasoned business executive will bring important insights in licensing strategy and contribute to Domain’s next phase of development   Strasbourg, France, June 12, 2019 – Domain Therapeutics, a biopharmaceutical company specialized in the discovery and development of new drug candidates targeting transmembrane receptors for unmet needs in neurology, oncology and rare diseases, today announces the appointment of Sylvie Ryckebusch to its board of directors.   Sylvie ...

READ MORE...


Vygon Asia donates chemo ports to Mount Miriam Cancer Hospital in Malaysia

Tuesday , 11 June 2019

Vygon Asia donates chemo ports to Mount Miriam Cancer Hospital in Malaysia Value Life – One Port One Life Program   Penang, Malaysia, June 11, 2019 – Vygon Asia today announces that it has donated 50 Vygon Polysite ISP implantable ports for patients undergoing chemotherapy at the Mount Miriam Cancer Hospital under the One Port One Life program.     Vygon’s Polysite ISP port is usually offered when a patient’s medical treatment requires regular...

READ MORE...


Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technolo

Wednesday , 05 June 2019

Service agreement gives Servier access to Yposkesi’s robust production capacity Suresnes and Corbeil-Essonnes, France, June 5, 2019 – Servier, an international independent pharmaceutical company, and Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, today announce that they have signed a manufacturing service agreement. Servier selected Yposkesi to develop and GMP manufacture lentiviral vectors to support allogenic CAR-T cell technology development. Cel...

READ MORE...


Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ata

Tuesday , 04 June 2019

Mataró, Barcelona, Spain and Charleroi, Belgium, June 4, 2019 - Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that the first patient has been dosed with its lead candidate, leriglitazone (MIN-102), in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia.  This first patient was dosed at the end of April at the Hospital La Paz (Madrid) by a team headed up by Dr. Francisco Javier Rodríguez de R...

READ MORE...


European Venture Capital Firm Seventure Partners  renews its support to Domain Therapeutics and ...

Tuesday , 28 May 2019

European Venture Capital Firm Seventure Partners  renews its support to Domain Therapeutics and invests €3.5M ($3.9M) to prepare next growth phase Strasbourg, France, May 28, 2019 –  Domain Therapeutics announces today that it has secured a €3.5M ($3.9M) investment from existing shareholder Seventure Partners, to accelerate its next growth phase. Since its inception in 2008, the French biopharma company has emerged as a key player in the field of discovery and e...

READ MORE...


Biomunex Pharmaceuticals establishes US subsidiary

Tuesday , 28 May 2019

Biomunex Inc. to focus on R&D and business development activities in the US   Paris, France, and Cambridge, MA, USA, May 28, 2019 - Biomunex Pharmaceuticals, a biopharmaceutical company focused on providing immuno-therapeutics through the discovery and development of bi- and multi-specific antibodies, today announces that it has established its US subsidiary, Biomunex Pharmaceuticals Inc., in Cambridge, Massachusetts, USA. The opening of this subsidiary is a first step in the ...

READ MORE...


GamaMabs Pharma to present updated results at 2019 ASCO Annual Meeting from the First-In-Human ...

Wednesday , 22 May 2019

GamaMabs Pharma to present updated results at 2019 ASCO Annual Meeting from the First-In-Human clinical study of murlentamab in advanced gynecological cancers  Objective responses, good safety and evidence of stimulation of the immune system observed under murlentamab (GM102) single agent and in combination with chemotherapy    Paris and Toulouse, France, May 22, 2019 – GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting t...

READ MORE...


Robocath strengthens its medical advisory board with international interventional cardiology experts

Tuesday , 21 May 2019

Rouen, France, May 21, 2019 - Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that Pr Haude, Dr Lorgat and Pr Nef have joined its medical advisory board. All are global experts and recognized leaders in interventional cardiology.   The board plays a key role in defining the clinical strategy of the company. Their clinical work ...

READ MORE...


Ophthalmology: Horus Pharma distributes ILUVIEN® in France

Tuesday , 21 May 2019

Horus Pharma is extending expertise to retinal field by introducing intravitreal implant to French market   Saint-Laurent du Var, France, May 21, 2019 – Horus Pharma, an independent laboratory specialized in ophthalmology, announces that it is now making ILUVIEN® available to French patients. ILUVIEN is owned by Alimera Sciences, Inc. (US).   ILUVIEN is an intravitreal implant which continuously releases a corticosteroid directly into the vitreous body...

READ MORE...


Bionure appoints Dr. Laurent Nguyen as CEO

Tuesday , 09 October 2018

Bionure appoints Dr. Laurent Nguyen as CEO The neuroprotection biotech also strengthens its scientific team with the arrival of Dr. Amit Bar-Or, a multiple sclerosis specialist, to the Scientific Advisory Board The ongoing phase 1 clinical trial of its neuroprotective and remyelinating compound BN201 is due for completion early 2019 Barcelona, Spain, October 9, 2018 - Bionure Farma, a biotech company specialized in neuroprotection, today announces the appointment of Dr. Laurent N...

READ MORE...


Featured Employers

© 2019 Jobsinpharma - 4ward Technologies Ltd All rights reserved.